MedTrace Logo

Early Screening of Pancreatic Lesions : Development of New Imaging Tools

NCT04007640 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2022-07-08

No results posted yet for this study

Summary

Obesity, diabetes and metabolic syndrome (MS) have all been associated with increase of pancreatic cancer (PK) risk. The precise role of obesity and diabetes and the pathways involved in the early oncogenic phases of PK associated with MS are not well known. The investigators hypothesize that it is possible to decipher this specific "fat-fibrosis-neoplastic sequence", to develop new imaging tools adapted to follow its progression, to test the benefit of treatments to slow this sequence and prevent the development of PK in obese and diabetic patients.This project is in line with a prevention strategy, by planning to understand the physiopathological pathways involved in MS leading to PK, to develop tools useful to screen early precancerous lesions in order to diagnose and treat patients at high risk, before cancer involvement.

This clinical trial is part of the INCA PAIR PANCREAS project : Early stages of pancreatic cancer associated with obesity and metabolic syndrome:

prevention and screening tools - Imaging of fatty pancreas in humans: correlation with pathological analysis, which includes 3 main coordinated objectives an in vitro approach an in vivo approach and this study (clinical approach).

Conditions

Interventions

RADIATION

MRI with additional sequences

MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences

RADIATION

MRI

MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences

PROCEDURE

Left pancreatectomy or pancreaticoduodenectomy

Histological analysis :

RADIATION

MRI with additional sequences

MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Ligue contre le cancer, France

    collaborator OTHER

  • Fondation ARC

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-18
Primary Completion
2023-10-27
Completion
2023-10-27

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04007640 on ClinicalTrials.gov